Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy

Cell Cycle

Volumn 10, Issue 14, 2011, Pages 2339-2343

  Cluzeau, Thomas ^a,b,c,d   Robert, Guillaume ^a,b,c   Puissant, Alexandre ^a,b,c   Jean Michel, Karsenti ^d   Cassuto, Jill Patrice ^d   Raynaud, Sophie ^e   Auberger, Patrick ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c Equipe Labellisée LIGUE 2015   (France)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^e PASTEUR HOSPITAL   (France)

Author keywords

AML; Apoptosis; Autophagy; Azacitidine; Caspases; MDS; Resistance

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AZACITIDINE; CASPASE; CATHEPSIN; CATHEPSIN B; CELL EXTRACT; IMATINIB; PROPIDIUM IODIDE; RESVERATROL;

APOPTOSIS; ARTICLE; AUTOPHAGY; BONE MARROW CELL; CELL LINE; CELL METABOLISM; CELL PERMEABILIZATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; MITOCHONDRIAL MEMBRANE; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION; PROTEIN MODIFICATION; WESTERN BLOTTING;

EID: 79960457766     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.14.16308     Document Type: Article

References (11)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361:1872-85.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-32.
3. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PloS One 2010; 5:9001.
4. Khan R, Schmidt-Mende J, Karimi M, Gogvadze V, Hassan M, Ekstrom TJ, et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008; 36:149-57.
5. Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, et al. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene 2007; 26:2445-58. (Pubitemid 46597264)
6. Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, et al. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PloS one 2009; 4:7889.
7. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S, et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2008; 70:1042-52.
8. Drexler HG, Dirks WG, Macleod RA. Many are called MDS cell lines: One is chosen. Leuk Res 2009; 33:1011-6.
9. Puissant A, Dufies M, Raynaud S, Cassuto JP, Auberger P. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. Leukemia 2010; 24:1099-101.
10. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23:7863-73. (Pubitemid 39457036)
11. Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, Gounon P, et al. Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. Autophagy 2009; 5:1092-8.